Delving into the Latest Updates on Kevirx, Inc. with Synapse

Overview

Tags

Urogenital Diseases

Hemic and Lymphatic Diseases

Endocrinology and Metabolic Disease

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	3
Hemic and Lymphatic Diseases	3
Neoplasms	3

Top 5 Drug Type	Count

Small molecule drug	3

Top 5 Target	Count

PRL-3(protein tyrosine phosphatase 4A3)	3

Protein tyrosine phosphatase type IVA member 3 (PTP4A3 or PRL-3) is a nonreceptor, oncogenic, dual-specificity phosphatase that is highly expressed in many human tumors, including ovarian cancer, and is associated with a poor patient prognosis. Recent studies suggest that PTP4A3 directly dephosphorylates SHP-2 phosphatase as part of a STAT3-PTP4A3 feedforward loop and directly dephosphorylates p38 kinase. The goal of the current study was to examine the effect of a PTP4A phosphatase inhibitor, 7-imino-2-phenylthieno[3,2-c]pyridine-4,6(5H,7H)-dione (JMS-053), on ovarian cancer STAT3, SHP-2, and p38 kinase phosphorylation. JMS-053 caused a concentration- and time-dependent decrease in the activated form of STAT3, Y⁷⁰⁵ phospho-STAT3, in ovarian cancer cells treated in vitro. In contrast, the phosphorylation status of two previously described direct PTP4A3 substrates, SHP-2 phosphatase and p38 kinase, were rapidly increased with JMS-053 treatment. We generated A2780 and OVCAR4 ovarian cancer cells resistant to JMS-053, and the resulting cells were not crossresistant to paclitaxel, cisplatin, or teniposide. JMS-053-resistant A2780 and OVCAR4 cells exhibited a 95% and 50% decrease in basal Y⁷⁰⁵ phospho-STAT3, respectively. JMS-053-resistant OVCAR4 cells had an attenuated phosphorylation and migratory response to acute exposure to JMS-053. These results support a regulatory role for PTP4A phosphatase in ovarian cancer cell STAT3 and p38 signaling circuits. SIGNIFICANCE STATEMENT: This study demonstrates that chemical inhibition of PTP4A phosphatase activity with JMS-053 decreases STAT3 activation and increases SHP-2 phosphatase and p38 kinase phosphorylation activation in ovarian cancer cells. The newly developed JMS-053-resistant ovarian cancer cells should provide useful tools to further probe the role of PTP4A phosphatase in ovarian cancer cell survival and cell signaling.

15 Jun 2022·Cancer Research

Abstract 5500: A PTP4A3 inhibitor reduces ovarian cancer dissemination and alters STAT3 and ERK activation

Author: Wipf, Peter ; Llaneza, Danielle C. ; Rastelli, Ettore J. ; Landen, Charles N. ; Sharlow, Elizabeth R. ; Isbell, Kelly N. ; Lazo, John S.

AbstractThe objective of this study was twofold: (1) to examine the pharmacological effects of a potent, allosteric, small molecule inhibitor (KVX-053 or 7-imino-2-phenylthieno[3,2-c]pyridine-4,6(5H,7H)-dione) of the oncogenic protein tyrosine phosphatase PTP4A3, which is overexpressed in human ovarian cancer and is associated with poor patient prognosis, and (2) to define alterations in ovarian cancer cells with acquired resistance to this PTP4A3 phosphatase inhibitor. PTP4A3 promotes cell migration, survival, metabolism, angiogenesis, and tumor formation, which are mediated at least partly by PTP4A3’s ability to function as a positive signal transducer capable of activating STAT3 and ERK1/2. We found KVX-053 inhibited the migration and, at higher concentrations, the viability of chemosensitive and chemoresistant human ovarian cancer cell lines in vitro. Using an established ovarian cancer metastasis prevention model in which taxane-resistant SKOV3TRip2 cells were injected i.p. followed by four treatments with 20 mg/kg KVX-053, we observed a median survival of 68 days compared to the median survival of 58 days in the vehicle treated mice. We also observed a statistically significant reduction in the number of tumor implantation sites with KVX-053 treatment. Since drug resistance frequently occurs with targeted cancer therapies, we next generated A2780 and OVCAR4 ovarian cancer cells that were 32- and 4-fold resistant to KVX-053, respectively. This was accomplished by using stepwise increased compound exposure over a 3-4 month period to probe acquired cellular resistance changes caused by KVX-053. The resulting KVX-053-resistant cells had similar in vitro growth rates with the wildtype cells and retained resistance to KVX-053 for at least one month when grown in the absence of the small molecule inhibitor. They were not cross-resistant to paclitaxel, cisplatin or teniposide but were cross-resistant to chemical analogs of KVX-053. The KVX-053-resistant A2780 cells exhibited a 95% decrease in the activated form of STAT3, Y705 phospho-STAT3, and a 57% decrease in the phosphorylation of a second activation site S727 without any marked differences in the total STAT3 levels. In contrast, phospho-ERK1/2 and total ERK1/2 were elevated in the ovarian cancer cells with stable resistance to KVX-053. These results further confirm the in vivo activity of KVX-053 against ovarian cancer and suggest that chronic KVX-053 exposure disrupts the PTP4A3/STAT3 and PTP4A3/ERK cellular signaling pathways.Citation Format: John S. Lazo, Kelly N. Isbell, Danielle C. Llaneza, Ettore J. Rastelli, Charles N. Landen, Peter Wipf, Elizabeth R. Sharlow. A PTP4A3 inhibitor reduces ovarian cancer dissemination and alters STAT3 and ERK activation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5500.

100 Deals associated with Kevirx, Inc.

Login to view more data

100 Translational Medicine associated with Kevirx, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

Login to view more data